NEC Display MD211G5 Diagnostic Display Receives FDA Clearance for Use in Tomosynthesis


NEC Display Solutions of America, a leading provider of commercial LCD display and projector solutions, today announced Food and Drug Administration clearance of its MultiSync® MD211G5 medical-grade monitor for use in tomosynthesis applications and full field digital mammography (FFDM).

The 21-inch NEC display is built for the displaying and viewing of digital images for diagnosis by trained physicians.

The five-megapixel, grayscale monitor, which also has been cleared for standard mammography, offers out-of-the-box factory DICOM calibration and uniformity control for consistent imaging across the entire screen. Its IPS panel features a 1200:1 contrast ratio and 500 cd/m2 of calibrated brightness. The MD211G5 display also comes with GammaCompMD QA software for managing conformance to the AAPM TG-18 standard.

“We are honored to receive FDA clearance for use in tomosynthesis and FFDM in addition to the earlier FDA 510(k) clearance for mammography,” said Art Marshall, Senior Product Manager for Professional Desktop and Medical Displays at NEC Display. “This demonstrates NEC’s commitment to providing the right products for every modality our customers require.”

Digital Breast Tomosynthesis (DBT), which combines tomography with digital radiography, renders breast images in 3D and accounts for more than one-half of the breast-imaging market, according to a report by iData Research.

A separate study by the University of Pennsylvania’s Perelman School of Medicine published in JAMA Oncology found that initial DBT screening led to, among other things, fewer patients called back for sometimes unnecessary imaging.

For more information about the MD211G5 display, please visit NEC Display.